Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years, Eli Lilly has been a fairly safe bet to ...
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...
Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...
4d
Hosted on MSNWill Eli Lilly Stock Keep Climbing? Q2 Trial Results Are CrucialEli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results